Lisa Mark

484 total citations
14 papers, 364 citations indexed

About

Lisa Mark is a scholar working on Public Health, Environmental and Occupational Health, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Lisa Mark has authored 14 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Public Health, Environmental and Occupational Health, 4 papers in Genetics and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Lisa Mark's work include Acute Lymphoblastic Leukemia research (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Lisa Mark is often cited by papers focused on Acute Lymphoblastic Leukemia research (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Lisa Mark collaborates with scholars based in United States. Lisa Mark's co-authors include William D. Boswell, Amy Caton, Casey L. O’Connell, Howard A. Liebman, Vinay Duddalwar, Cheryl Vigen, Dan Douer, Ann Mohrbacher, Laleh Ramezani and Pedram Razavi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Thrombosis and Haemostasis.

In The Last Decade

Lisa Mark

14 papers receiving 356 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Mark United States 6 206 113 109 106 77 14 364
Ángeles Blanco‐Molina Spain 10 265 1.3× 20 0.2× 203 1.9× 35 0.3× 37 0.5× 23 371
A. Van Loo Belgium 6 56 0.3× 16 0.1× 33 0.3× 36 0.3× 23 0.3× 14 293
Helen Dodsworth United Kingdom 7 125 0.6× 18 0.2× 80 0.7× 28 0.3× 10 0.1× 17 319
B Charbonnier France 4 625 3.0× 91 0.8× 502 4.6× 16 0.2× 5 0.1× 10 687
Chris Ward Australia 6 86 0.4× 11 0.1× 61 0.6× 4 0.0× 25 0.3× 7 241
L. Vickars Canada 7 517 2.5× 76 0.7× 369 3.4× 13 0.1× 3 0.0× 10 565
Pablo Javier Marchena Spain 11 314 1.5× 106 0.9× 235 2.2× 5 0.0× 4 0.1× 24 383
J. Paul Scott United States 5 42 0.2× 44 0.4× 53 0.5× 6 0.1× 31 0.4× 9 267
A. Merah France 10 275 1.3× 130 1.2× 140 1.3× 10 0.1× 8 0.1× 24 315
Gema Fernández Fresnedo Spain 11 10 0.0× 8 0.1× 70 0.6× 30 0.3× 36 0.5× 49 393

Countries citing papers authored by Lisa Mark

Since Specialization
Citations

This map shows the geographic impact of Lisa Mark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Mark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Mark more than expected).

Fields of papers citing papers by Lisa Mark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Mark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Mark. The network helps show where Lisa Mark may publish in the future.

Co-authorship network of co-authors of Lisa Mark

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Mark. A scholar is included among the top collaborators of Lisa Mark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Mark. Lisa Mark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Douer, Dan, Ibrahim Aldoss, Matthew A. Lunning, et al.. (2014). Pharmacokinetics-Based Integration of Multiple Doses of Intravenous Pegaspargase in a Pediatric Regimen for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(9). 905–911. 84 indexed citations
3.
4.
O’Connell, Casey L., Pedram Razavi, Lisa Mark, et al.. (2010). Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning. Journal of Thrombosis and Haemostasis. 9(2). 305–311. 107 indexed citations
5.
Ailawadhi, Sikander, Michael Keng, Andrew Hendifar, et al.. (2009). High-Dose Cyclophosphamide: An Effective Non-Transplant Salvage Option in Relapsed/Refractory Multiple Myeloma.. Blood. 114(22). 4947–4947. 2 indexed citations
6.
7.
8.
O’Connell, Casey L., William D. Boswell, Pedram Razavi, et al.. (2008). Unsuspected Pulmonary Emboli Identified on Routine Cancer Staging MDCT Scans: Impact on Cancer Survival. Blood. 112(11). 3818–3818. 5 indexed citations
9.
10.
Douer, Dan, Kristy Watkins, Ilene C. Weitz, et al.. (2006). Treatment of Non-APL Acute Myelogenous Leukemia with Intravenous Arsenic Trioxide Plus Ascorbic Acid.. Blood. 108(11). 1959–1959. 6 indexed citations
11.
O’Connell, Casey L., William D. Boswell, Vinay Duddalwar, et al.. (2006). Unsuspected Pulmonary Emboli in Cancer Patients: Clinical Correlates and Relevance. Journal of Clinical Oncology. 24(30). 4928–4932. 110 indexed citations
12.
Douer, Dan, Kristy Watkins, Ilene C. Weitz, et al.. (2005). Treatment of Non-APL Acute Myelogenous Leukemia with Intravenous Arsenic Trioxide Plus Ascorbic Acid.. Blood. 106(11). 4603–4603. 7 indexed citations
13.
Mohrbacher, Ann, Anil Tulpule, Byron M. Espina, et al.. (2004). Results of a pilot trial of fludarabine, mitoxantrone and rituximab in mantle cell lymphoma. Journal of Clinical Oncology. 22(14_suppl). 6697–6697. 1 indexed citations
14.
Mohrbacher, Ann, Anil Tulpule, Byron M. Espina, et al.. (2004). Results of a pilot trial of fludarabine, mitoxantrone and rituximab in mantle cell lymphoma. Journal of Clinical Oncology. 22(14_suppl). 6697–6697. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ángeles Blanco‐Molina Breakdown of academic impact, for papers by A. Van Loo Breakdown of academic impact, for papers by Helen Dodsworth Breakdown of academic impact, for papers by B Charbonnier Breakdown of academic impact, for papers by Chris Ward Breakdown of academic impact, for papers by L. Vickars Breakdown of academic impact, for papers by Pablo Javier Marchena Breakdown of academic impact, for papers by J. Paul Scott Breakdown of academic impact, for papers by A. Merah Breakdown of academic impact, for papers by Gema Fernández Fresnedo
Rankless by CCL
2026